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CLINICAL INQUIRIES
to aPTT levels (goal 70–100s), while low-
molecular-weight heparin group received
subcutaneous dalteparin 115 IU/kg twice
daily adjusted to target antifactor Xa levels
of 1 to 1.5 IU/mL 3 hours after injection.
After 7 days, both groups received prophy-
lactic doses of dalteparin throughout the
remainder of pregnancy. There were no
significant differences in outcome includ-
ing bleeding or fetal effects. No cases of
thrombocytopenia or pulmonary embolus
were seen. There was 1 case of progressive
thrombosis for a patient on low-molecular-
weight heparin.
■ Evidence summary
Pulmonary embolism remains one of the
leading causes of maternal mortality in
developed nations. For nonpregnant popu-
lations, low-molecular-weight heparin has
equal efficacy as unfractionated heparin
with a lower overall mortality.1,2
The only direct comparison of unfrac-
tionated with low-molecular-weight
heparin for treatment of VTE in pregnan-
cy was a prospective cohort study of 31
patients.3 For the initial week of treatment,
the unfractionated heparin group received
an IV bolus followed by infusion titrated
How can we best treat and monitor 
VTE during pregnancy?
Unfractionated heparin and low-molecular-weight
heparin are equally effective for the treatment of
acute venous thromboembolism (VTE) in pregnancy
(strength of recommendation [SOR]: C; based on
expert opinion and 1 low-power cohort study).
Low-molecular-weight heparin may be associated
with fewer bleeding events than unfractionated
heparin (SOR: B; extrapolated from a randomized
controlled trial of thromboprophylaxis in pregnancy). 
Unfractionated heparin for treatment of VTE
should be given by IV bolus followed by continuous
infusion, maintaining the activated partial thrombo-
plastin time (aPTT) in therapeutic range for at least 
5 days, followed by subcutaneous heparin 2 or 3
times daily to maintain aPTT levels 1.5 to 2.5 times
normal for at least 3 months (SOR: C, expert 
opinion). Low-molecular-weight heparin should be
initially dosed based on weight as for nonpregnant
patients, then adjusted to goal peak antifactor Xa
levels of 0.5–1.2 IU/mL (SOR: C; expert opinion). 
The US Food and Drug Administration has labeled
warfarin as category X, indicating that it is 
contraindicated during pregnancy due to fetal loss 
and probable teratogenicity.
E V I D E N C E - B A S E D A N S W E R
Safety is most important when treating 
pregnant women
We have enough evidence to conclude that 
unfractionated heparin and low-molecular-weight
heparin are both effective treatments for acute
VTE in pregnant women. Unfortunately, we don’t
know whether 1 treatment is safer or more 
effective than the other. The safety issue is the
most important consideration in treating pregnant
women. A large number of patients would need to
be studied to identify a small but significant 
difference between the 2. We as clinicians would
want to know if 1 therapy had even a slightly
increased risk of a catastrophic harm. Clinical
experience is not enough to tell us that; we need
more research.
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Low-molecular
weight and
unfractionated
heparin are 
both effective
treatments 
for acute VTE in
pregnant women
FAST TRACK
One randomized controlled trial com-
pared unfractionated with low-molecular-
weight heparin for VTE prophylaxis
among 107 high-risk pregnant patients.4
The unfractionated heparin group received
7500 IU subcutaneously twice daily adjust-
ed to aPTT levels, while the dalteparin
group received weight-adjusted doses to
target antifactor Xa levels >0.2 IU/mL at 3
hours. No thromboembolic complications
occurred in either group (95% confidence
interval, 0 to 2 in both groups). Minor
bleeding complications were significantly
more common with unfractionated
heparin than with low-molecular-weight
heparin. Two bleeds requiring transfusion
and 2 lumbosacral compression fractures
were also observed in the unfractionated
heparin group, compared with none in the
dalteparin group (difference not statistical-
ly significant).
Heparinoid metabolism appears to sig-
nificantly alter in pregnancy. Several stud-
ies of low-molecular-weight heparin for
the treatment of VTE in pregnancy used
target antifactor Xa levels of 0.5 to 1.5 at
3 hours and found patients often need
doses greater than those used for nonpreg-
nant patients.3,5–7 The only study of unfrac-
tionated heparin for the treatment of VTE
in pregnancy used aPTT levels extrapolat-
ed from nonpregnant patients, with a
mean heparin dose of 25,430 IU/d, similar
to mean doses for nonpregnant patients.3
There are no studies of repeat lower
extremity ultrasounds for pregnant
patients; however, 1 study of nonpregnant
patients revealed proximal extension of
deep venous thrombosis despite anticoagu-
lation predicted increased risk of pul-
monary embolism.8
Recommendations from others
Both the American College of Obstetrics
and Gynecologists9 and the American
College of Chest Physicians10 recommends
treating acute VTE in pregnancy with
either weight-adjusted-dose low-molecu-
lar-weight heparin (goal antifactor Xa 
levels, 0.5–1.2) throughout pregnancy or
full-dose intravenous unfractionated
heparin, followed by adjusted-dose unfrac-
tionated or low-molecular-weight heparin,
for the remainder of the pregnancy and at
least 6 weeks postpartum. 
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